Skip to main content

Lupus

      RT @uptoTate: Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of
      Combined estrogen-progestin contraception in SLE patients with positive aPL conferred an increased risk of thrombosis relative to progestin-only contraception. Abs 0943 #ACR22 @RheumNow https://t.co/B2Wmhlz6at https://t.co/YlvqoYY8FN
      RT @ericdeinmd: Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE?
      363 pt P2, double-blind PBO-controlled 48 w
      2 years ago
      Ab1117 #ACR22 Deucravacitinib: TYK2 inhibitor in active SLE? 363 pt P2, double-blind PBO-controlled 48 wk study DEUC 3 mg BID, 6 BID, 12 QB vs PBO: At 32wk: DEUC 3BID & 6BID > PBO, sustained across all groups at 48wk. AEs: similar bw PBO and DEUC. No VTE @RheumNow #ACRBest https://t.co/uamJe05odq
      RT @uptoTate: Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at ris
      Interstitial inflammation in the entire cortical parenchyma in areas w/ and w/o fibrosis identifies at risk SLE pts for CKD progression. Abs 0634 #ACR22 @RheumNow https://t.co/3iBYHPyYXL https://t.co/iSwblT2Amm
      RT @KDAO2011: Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less th
      2 years ago
      Most rheums round down on dosing because of the weight based recc's, but hydroxychloroquine dosing less than 5 Mg/kg/day leads to increased hospitalizations for #SLE flares abst#1654 #ACR22 #PressConference @rheumnow https://t.co/GGnnl14cy9
      RT @KDAO2011: Stop repeating the #ANA test!
      46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUt
      2 years ago
      Stop repeating the #ANA test! 46% of all ANA tests were repeat tests in this study. #HealthCareCost #NoUtility #ChooseWisely abst#1278 @rheumnow #ACR22 https://t.co/K7oyqJYvi9
      RT @uptoTate: Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater
      Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ
      RT @EBRheum: I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence!

      Receiving less HCQ =
      2 years ago
      I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence! Receiving less HCQ = more damage and more CVD Observational, not clearly causal, but should make you wonder... Are we sure we should be shooting for <5mg/kg/day? #ACR22 @RheumNow #0982 https://t.co/SuAwSumgu1
      RT @uptoTate: In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe in
      In non-renal SLE, BEL associated w/ a lower risk of severe infection and hospitalizations due to severe infection compared to MTX, AZA, MMF. Abs 0349 #ACR22 @RheumNow https://t.co/0EBpCMPOqF https://t.co/vdxKVJSaZA
      RT @RichardPAConway: Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stab
      Isenberg et al. Atacicept 150mg in SLE. Reduced flare 36% vs 53%, delayed time to first flare, stabalised renal function (vs decline in PBO), less steroid increase (14% vs 36%), UPCR declined (vs increase in PBO) @RheumNow #ACR22 Abstr#1001 https://t.co/FRWcTAgCrn https://t.co/Amkg84OX2x